Skip to main content
. 2021 Aug 26;10:124. doi: 10.1186/s13756-021-00991-y

Table 3.

Antibiotic resistance profiles of major bacterial pathogens isolated in patients’ samples

Antibiotic n (%) EC (%) EB (%) ECp (%) KP (%) MS (%) SA (%) SP (%) SM (%)
Fluoroquinolones
CIP 90 (14.7) 41.9 50 81.8 61.5 66.7 26.7 0 100
NOR 35 (5.7) 61.5 NT 100 0 NT 100 100 66.7
Aminoglycosides
GEN 64 (10.5) 58.3 57.1 100 62.5 100 28.6 0 0
AMK 39 (6.4) 30 0 0 11.1 0 50 0 0
Cephalosporins
CRO_CTX 56 (9.2) 73.1 100 100 72.7 100 33.3 100 100
CAZ 31 (5.1) 100 100 100 100 100 NT 100 100
CXM 29 (4.7) 100 NT NT 0 NT 0 NT NT
Carbapenems
IPM 39 (6.4) 0 NT 20 0 NT 0 NT 0
MEM 25 (4.1) 0 0 83.3 0 0 NT 0 0
Tetracyclines
TET 23 (3.8) 33.3 NT 50 NT NT 60 NT 100
DOX 16 (2.6) 50 100 NT 0 NT 0 NT NT
Penicillin
Augmentin 19 (3.1) 100 100 100 100 100 NT NT 100
OXA 13 (2.1) 100 NT NT 100 NT 83.3 NT NT
PIP 12 (2.0) 100 NT NT 100 100 NT NT NT
Macrolides
CLR 18 (2.9) 62.5 75 NT NT NT 16.7 NT NT
ERY 14 (2.3) 100 100 NT 0 NT 0 NT NT
Others (lincosamides, chloramphenicol and glycopeptides)
CLI 37 (6.1) 78.9 33.3 NT 100 NT 27.3 NT NT
CHL 34 (5.6) 33.3 100 100 81.8 100 0 NT 100
VAN 16 (2.6) 100 NT 14.3 NT NT NT NT NT

EC: E. coli; KP: K. pneumonae; SA: S. aureus; ECp: Enterococcus spp; EB: Enterobacter spp; MS: Morganella spp; SM: S. marcescens; SP: Salmonella spp

CIP: ciprofloxacin; NOR; norfloxacin; GEN: gentamycin; AMK: amikacine; CRO_CTX: ceftriaxone-cefotaxime; CAZ: ceftazidime; CXM: cefuroxime; IPM: impinem; MEM: meropenem; TET: tetracycline; DOX: doxycycline; OXA: oxacyline; PIP: piperacillin; CLR: clarithromycin; ERY: erythromycin; CLI: clindamycin; CHL: chloramphenicol; VAN: vancomycin. NT: Not tested